Amgen and the University of Washington’s Institute for Protein Design (IPD) entered a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to drug research.   This will include optimizing Amgen’s repertoire of BiTE® (bispecific T cell engager) antibodies, with the goal of expanding the types of tumors that can be targeted with these molecules. IPD’s expertise could al...